In order to explore the possible effects of ERK/MEK inhibition on SRC activity, we treated the matched pair of isogenic CRC cell lines (+/– PTPRS) with an ERK inhibitor and followed SRC-Y419 phosphorylation during early and extended drug treatment. This evidence concerns the gene MAP2K7 and colorectal carcinoma.